ReachRxResearch
Home
Research
Sign Up
Systemic Mitochondrial DNA Kinetics After cDCD Lung Transplantation Do Not Reflect Donor Warm Ischemic Injury: DACMEDAMPs, a Prospective multicenter translational study
Back to Research Hub
  1. Home
  2. Research Hub
  3. Systemic Mitochondrial DNA Kinetics Afte…

Systemic Mitochondrial DNA Kinetics After cDCD Lung Transplantation Do Not Reflect Donor Warm Ischemic Injury: DACMEDAMPs, a Prospective multicenter translational study

American Journal of Transplantation·August 13
SurgeryLimited evidenceDonation After Circulatory Determination Of DeathIschemia-Reperfusion InjuryLung TransplantationProspective Multicenter Observational StudyOrgan TransplantationAdult

Summary

View source

What was studied

This prospective multicenter observational study compared plasma cell-free mitochondrial DNA (cf-mtDNA) kinetics in matched adult lung transplant recipients from controlled donation after circulatory determination of death (cDCD) vs. donors after brain death (DBD), evaluating whether cf-mtDNA levels reflect donor warm ischemic injury.

Key findings

Donor plasma cf-mtDNA levels were similar between cDCD and DBD groups; a donor type-by-time interaction emerged at 72 hours post-transplant, but neither total nor functional warm ischemia time was independently associated with cf-mtDNA concentrations. Exploratory data showed graft-derived mtDNA declined from reperfusion to 72 hours even as total cf-mtDNA rose, suggesting recipient-driven inflammation rather than donor warm ischemia drives post-transplant systemic cf-mtDNA dynamics.

Study limitations

Observational design limits causal inference; exploratory donor-derived cf-mtDNA analysis was hypothesis-generating only; the matched cohort may not fully represent all cDCD lung transplant scenarios.

Clinical implications

Systemic cf-mtDNA should not be used as a surrogate marker for donor warm ischemic injury after cDCD lung transplantation. Clinicians interpreting elevated post-transplant cf-mtDNA levels should consider recipient inflammatory responses as the primary driver.

Caveats

  • Sample size (n) is not reported in the abstract; level of evidence assigned as 3 based on prospective matched observational design, but may warrant revision if the cohort is small.
  • Study was published August 13, 2026; today's date is August 30, 2026, so this is very recent and has not yet accumulated citations or external validation.
  • The donor-derived cf-mtDNA analysis is explicitly described as exploratory — findings in that subsection should be interpreted cautiously.

Related Questions

Explore related topics

What biomarkers best predict primary graft dysfunction after cDCD lung transplantation?How does ischemia-reperfusion injury differ between cDCD and DBD lung transplants clinically?What is the role of cell-free mitochondrial DNA as a danger signal in solid organ transplantation?

Publication Details

Year
2026
Journal
American Journal of Transplantation
Source
View article
Keep scrolling
More content below.
Up Next